A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Moderate Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Daridorexant (Primary)
- Indications Insomnia
- Focus Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 20 Sep 2019 Status changed from recruiting to completed.
- 18 Sep 2019 Planned End Date changed from 31 Jul 2019 to 30 Sep 2019.
- 18 Sep 2019 Planned primary completion date changed from 31 Jul 2019 to 30 Sep 2019.